Su Y, Wang J, Guo J, Liu X, Yang X, Cheng R
Sci Rep. 2024; 14(1):31909.
PMID: 39738411
PMC: 11685987.
DOI: 10.1038/s41598-024-83452-x.
Casamitjana A, Mancini M, Robinson E, Peter L, Annunziata R, Althonayan J
bioRxiv. 2024; .
PMID: 39282320
PMC: 11398399.
DOI: 10.1101/2024.02.05.579016.
Hu Y, Zhang K
Front Oncol. 2024; 14:1362990.
PMID: 38826787
PMC: 11140042.
DOI: 10.3389/fonc.2024.1362990.
Manning P, Srinivas S, Bolar D, Rajaratnam M, Piccioni D, McDonald C
Front Radiol. 2024; 4:1345465.
PMID: 38562528
PMC: 10982483.
DOI: 10.3389/fradi.2024.1345465.
Lambrecht S, Liu D, Dzaye O, Kamson D, Reis J, Liebig T
Brain Sci. 2024; 14(2).
PMID: 38391701
PMC: 10886779.
DOI: 10.3390/brainsci14020126.
Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient.
Kamimura K, Nakano T, Hasegawa T, Nakajo M, Yamada C, Kamimura Y
Cancer Imaging. 2023; 23(1):114.
PMID: 38037172
PMC: 10691025.
DOI: 10.1186/s40644-023-00639-7.
Reproducibility of rCBV in glioblastomas using T2*-weighted perfusion MRI: an evaluation of sampling, normalization, and experience.
Yuzkan S, Mutlu S, Karagulle M, Ozdemir M, Ozgul H, Arikan M
Diagn Interv Radiol. 2023; 30(2):124-134.
PMID: 37789677
PMC: 10916530.
DOI: 10.4274/dir.2023.232442.
Conventional and Advanced Imaging Techniques in Post-treatment Glioma Imaging.
Li A, Iv M
Front Radiol. 2023; 2:883293.
PMID: 37492665
PMC: 10365131.
DOI: 10.3389/fradi.2022.883293.
Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.
Wang F, Zhou X, Chen R, Kang J, Yang X, Lin J
Eur Radiol. 2023; 33(12):8800-8808.
PMID: 37439934
DOI: 10.1007/s00330-023-09917-1.
Radiological Biomarkers for Brain Metastases Prognosis: Quantitative Magnetic Resonance Imaging (MRI) Modalities As Non-invasive Biomarkers for the Effect of Radiotherapy.
Eraky A
Cureus. 2023; 15(4):e38353.
PMID: 37266043
PMC: 10229388.
DOI: 10.7759/cureus.38353.
Neuroimaging for differential diagnosis of transient neurological attacks.
Wang Y, Zha H
Brain Behav. 2022; 12(12):e2780.
PMID: 36350080
PMC: 9759151.
DOI: 10.1002/brb3.2780.
Differentiation of high grade glioma and solitary brain metastases by measuring relative cerebral blood volume and fractional anisotropy: a systematic review and meta-analysis of MRI diagnostic test accuracy studies.
Fioni F, Chen S, Lister I, Ghalwash A, Long M
Br J Radiol. 2022; 96(1141):20220052.
PMID: 36278795
PMC: 10997014.
DOI: 10.1259/bjr.20220052.
[Current Applications and Future Perspectives of Brain Tumor Imaging].
Park J, Kim H
Taehan Yongsang Uihakhoe Chi. 2022; 81(3):467-487.
PMID: 36238631
PMC: 9431910.
DOI: 10.3348/jksr.2020.81.3.467.
Challenges and opportunities for advanced neuroimaging of glioblastoma.
Henssen D, Meijer F, Verburg F, Smits M
Br J Radiol. 2022; 96(1141):20211232.
PMID: 36062962
PMC: 10997013.
DOI: 10.1259/bjr.20211232.
Reliability of dynamic susceptibility contrast perfusion metrics in pre- and post-treatment glioma.
Kouwenberg V, van Santwijk L, Meijer F, Henssen D
Cancer Imaging. 2022; 22(1):28.
PMID: 35715866
PMC: 9205029.
DOI: 10.1186/s40644-022-00466-2.
Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma.
Woodall R, Sahoo P, Cui Y, Chen B, Shiroishi M, Lavini C
Neurooncol Adv. 2022; 3(1):vdab174.
PMID: 34988454
PMC: 8715899.
DOI: 10.1093/noajnl/vdab174.
Preliminary study of multiple b-value diffusion-weighted images and T1 post enhancement magnetic resonance imaging images fusion with Laplacian Re-decomposition (LRD) medical fusion algorithm for glioma grading.
Khorasani A, Tavakoli M, Saboori M, Jalilian M
Eur J Radiol Open. 2021; 8:100378.
PMID: 34632000
PMC: 8487979.
DOI: 10.1016/j.ejro.2021.100378.
Differentiating Glioblastomas from Solitary Brain Metastases: An Update on the Current Literature of Advanced Imaging Modalities.
Fordham A, Hacherl C, Patel N, Jones K, Myers B, Abraham M
Cancers (Basel). 2021; 13(12).
PMID: 34199151
PMC: 8231515.
DOI: 10.3390/cancers13122960.
Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and F-FMISO PET.
Huang S, Michalek J, Reardon D, Wen P, Floyd J, Fox P
Sci Rep. 2021; 11(1):7632.
PMID: 33828310
PMC: 8027395.
DOI: 10.1038/s41598-021-84331-5.
Accuracy of apparent diffusion coefficient in differentiation of glioblastoma from metastasis.
Beig Zali S, Alinezhad F, Ranjkesh M, Daghighi M, Poureisa M
Neuroradiol J. 2021; 34(3):205-212.
PMID: 33417503
PMC: 8165902.
DOI: 10.1177/1971400920983678.